

# Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial

Robbert J. de Winter<sup>1</sup>, MD, PhD; Azfar Zaman<sup>2</sup>, MD; Hironori Hara<sup>1,3</sup>, MD; Chao Gao<sup>3,4</sup>, MD; Masafumi Ono<sup>1,3</sup>, MD; Scot Garg<sup>5</sup>, MD, PhD; Pieter C. Smits<sup>6</sup>, MD, PhD; Pim A.L. Tonino<sup>7</sup>, MD, PhD; Sjoerd H. Hofma<sup>8</sup>, MD, PhD; Raul Moreno<sup>9</sup>, MD, PhD; Anirban Choudhury<sup>10</sup>, MD; Ivo Petrov<sup>11</sup>, MD; Angel Cequier<sup>12</sup>, MD; Antonio Colombo<sup>13,14</sup>, MD; Upendra Kaul<sup>15</sup>, MD, PhD; Yoshinobu Onuma<sup>3\*</sup>, MD, PhD; Patrick W. Serruys<sup>3,16</sup>, MD, PhD

1. Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 2. Newcastle Freeman Hospital, Newcastle University, and Newcastle upon Tyne Hospitals NHS Trust, Newcastle, United Kingdom; 3. Department of Cardiology, National University of Ireland Galway, Galway, Ireland; 4. Department of Cardiology, Radboud University, Nijmegen, the Netherlands; 5. Department of Cardiology, Royal Blackburn Hospital, Blackburn, United Kingdom; 6. Maasstad Ziekenhuis, Rotterdam, the Netherlands; 7. Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands; 8. Medical Centre Leeuwarden, Leeuwarden, the Netherlands; 9. Cardiology Department, La Paz University Hospital, Madrid, Spain; 10. Department of Cardiology, University Hospital of Wales, Cardiff, United Kingdom; 11. Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria; 12. Bellvitge University Hospital, University of Barcelona, IDIBELL, Barcelona, Spain; 13. Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy; 14. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 15. Academics and Research, Batra Hospital and Medical Research Center, New Delhi, India; 16. NHLI, Imperial College London, London, United Kingdom on behalf of the TALENT Investigators

R.J. de Winter, A. Zaman and H. Hara contributed equally to this paper.

This paper also includes supplementary data published online at: <https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-21-00766>

## KEYWORDS

- clinical trials
- drug-eluting stent
- innovation

## Abstract

**Background:** In the TALENT study, the sirolimus-eluting ultrathin strut Supraflex stent was non-inferior to the XIENCE stent for a device-oriented composite endpoint (DoCE: defined as cardiac death, target-vessel myocardial infarction [TV-MI], or clinically indicated target lesion revascularisation [CI-TLR]) at 12 months.

**Aims:** This study investigated the 3-year outcomes of the TALENT trial and long-term impact of ultrathin drug-eluting stents (DES), compared to the XIENCE everolimus-eluting thin stent.

**Methods:** The TALENT trial is a prospective, multicentre, randomised all-comers trial comparing the Supraflex sirolimus-eluting stent with the XIENCE everolimus-eluting stent, with planned follow-up for 3 years.

**Results:** The TALENT trial enrolled 1,435 patients (Supraflex n=720, XIENCE n=715) with 3-year follow-up data available in 97.8% in the Supraflex group, and in 98.9% in the XIENCE group. At 3 years, DoCE occurred in 57 patients (8.1%) in the Supraflex group, and in 66 patients (9.4%) in the XIENCE group (p=0.406). There were no significant between-group differences in rates of cardiac death, TV-MI or CI-TLR. The rates of definite or probable stent thrombosis were low and similar between groups (1.1% vs 1.4%; p=0.640). In a meta-analysis of long-term follow-up (3-5 years), ultrathin strut DES tended to reduce DoCE (relative risk 0.89 [0.79-1.01]; p=0.068), compared to thicker strut DES. The risks for cardiac death and definite or probable stent thrombosis were similar between ultrathin strut DES and thicker strut DES.

**Conclusions:** At 3-year follow-up, the use of the Supraflex stent was at least as safe and efficacious as the XIENCE stent in an all-comers population. ClinicalTrials.gov: NCT02870140

\*Corresponding author: Professor of Interventional Cardiology, National University of Ireland, Galway (NUIG), University Road, Galway H91 TK33, Ireland. E-mail: [yoshinobuonuma@gmail.com](mailto:yoshinobuonuma@gmail.com)

## Abbreviations

<b>CI</b>	confidence interval
<b>CI-TLR</b>	clinically indicated target lesion revascularisation
<b>DES</b>	drug-eluting stent
<b>DoCE</b>	device-oriented composite endpoint
<b>EES</b>	everolimus-eluting stent
<b>ITT</b>	intention-to-treat
<b>MI</b>	myocardial infarction
<b>PP</b>	per protocol
<b>PoCE</b>	patient-oriented composite endpoint
<b>RR</b>	relative risk
<b>SES</b>	sirolimus-eluting stent
<b>TV</b>	target vessel

## Introduction

Stents with thinner struts have been shown to reduce acute thrombogenicity and promote faster endothelialisation, compared to stents with thicker struts<sup>1-3</sup>. One hypothesis behind this is that protruding thicker struts disrupt laminar flow, inducing flow disturbances, which can activate a platelet-signalling procoagulation pathway<sup>1,4</sup>. The physiological benefits and improved fluid dynamics with thinner struts may be partly responsible for the reduced rates of restenosis, stent thrombosis, and myocardial infarction (MI) observed with contemporary second-generation drug eluting stents (DES), which all have strut thicknesses of <100 µm, when compared to first-generation DES, which had strut thicknesses of >132 µm. The development of ultrathin strut stents, with strut thicknesses of <70 µm may further improve event-free survival compared to thin strut DES (second-generation DES).

The Supraflex stent (Sahajanand Medical Technologies) is a sirolimus-eluting stent (SES) with a biodegradable polymeric coating and 60 µm ultrathin struts. In the TALENT study, the Supraflex SES was non-inferior to the XIENCE durable polymer everolimus-eluting stent (EES; Abbot Vascular), for a device-oriented composite endpoint (DoCE) of cardiac death, target-vessel myocardial infarction (TV-MI), or clinically indicated target lesion revascularisation (CI-TLR) at 12 months<sup>5,6</sup>. The longer-term outcomes with ultrathin DES are currently limited, and therefore we investigated the final 3-year outcomes after implantation of the Supraflex SES as compared to the XIENCE EES in the TALENT all-comers trial.

## Methods

### STUDY DESIGN AND POPULATION

The design and 2-year results of the TALENT trial have been reported previously<sup>5-7</sup>. In brief, the TALENT trial is a prospective, multicentre, single-blinded, all-comers, randomised controlled trial, allocating patients in a 1:1 ratio to either the Supraflex SES or XIENCE EES. Twenty-three sites in Europe enrolled patients from October 2016 to July 2017. The primary endpoint of the study was a non-inferiority comparison at 12 months of a DoCE, defined as a composite of cardiac death, TV-MI, and CI-TLR. The composite secondary endpoints were a patient-oriented composite

endpoint (PoCE) of all-cause death, any MI, and any revascularisation, and target vessel failure (TVF), a composite of cardiac death, TV-MI, and clinically indicated target vessel revascularisation (CI-TVR). Stent thrombosis – a safety indicator – was defined as per the Academic Research Consortium definition<sup>8</sup>. MI was defined according to the Society for Cardiovascular Angiography and Interventions consensus for periprocedural MI (when occurring 48 hrs or less after the index procedure) or according to the Third Universal Definition for MI<sup>9,10</sup>. Clinical data were adjudicated by an independent clinical event committee, blinded to stent allocation.

Patients with stable coronary artery disease received dual antiplatelet therapy (DAPT) for >6 months after percutaneous coronary intervention (PCI), followed by aspirin monotherapy indefinitely. Patients with acute coronary syndrome received DAPT for >12 months after PCI, followed by aspirin monotherapy indefinitely. The protocol prespecified patient follow-up up to 3 years.

All patients provided written informed consent to participate in the study. The study protocol of the TALENT trial was approved by institutional ethics committees of participating institutions and central regulatory bodies for each country, and was conducted according to the Declaration of Helsinki and Good Clinical Practice.

### STUDY STENTS

Supraflex is a new-generation metallic stent consisting of an L605 cobalt-chromium alloy platform with ultrathin struts (60 µm) across all stent diameters, flexible S-link connectors, and a biodegradable polymeric matrix coating. Sirolimus, at a concentration of 1.4 µg/mm<sup>2</sup>, together with the polymeric matrix, is coated on the conformal surface of the stent, with an average coating thickness of 4-5 µm. Seventy percent of the sirolimus is eluted in the first 7 days, with the remainder released over the following 48 days. The polymer gradually degrades over 9-12 months. The crossing profile of the Supraflex is 0.99 mm (the crossing profile of the newest XIENCE Alpine EES is 1.10 mm and of the XIENCE Sierra EES is 0.99 mm).

The control stent used in the study was the XIENCE EES, which has a cobalt chromium alloy platform and a strut thickness of 81 µm. It has an 8 µm thick durable polymer coated with everolimus at a dose of 1 µg/mm<sup>2</sup>, which is completely eluted over 120 days.

### META-ANALYSIS

Randomised clinical trials comparing ultrathin strut DES (strut thickness <70 µm) and thicker strut DES (strut thickness ≥81 µm) with at least 3-year outcomes were searched from PubMed, EMBASE, and abstracts and presentations from major cardiovascular meetings between January 2010 and October 2021 (**Supplementary Table 1**). The meta-analytic summary estimates (relative risk [RR] with 95% confidence interval [CI]) for the ultrathin strut DES versus thicker strut DES in terms of DoCE, its individual components, definite or probable stent thrombosis, and

all-cause death at the time of last available follow-up were evaluated using results reported in intention-to-treat (ITT) analyses. All outcomes were calculated using both the fixed-effects model and the random-effects model of DerSimonian and Laird<sup>11</sup>. This was done to compare the fixed- and random-effects estimates of the intervention as recommended by the Cochrane Collaboration, given that we anticipated some heterogeneity ( $I^2 > 0$ ). If the estimates are similar, then any small-study effects have little impact on the intervention effect estimate. Heterogeneity was assessed using the  $I^2$  statistic, with  $I^2 < 25\%$  considered low,  $I^2 \geq 25\%$  and  $\leq 75\%$  considered moderate, and  $I^2 > 75\%$  considered high<sup>12,13</sup>. When heterogeneity was moderate or high, the L'Abbé plot was demonstrated. Publication bias was visually inspected using a funnel plot. Risk of bias was assessed according to the Cochrane Collaboration's tool<sup>14</sup>.

## STATISTICAL ANALYSIS

All patients in the ITT analysis were analysed according to their assigned treatment group, regardless of the actual treatment received. Patients who were randomised to a treatment group and only received that assigned study stent, were included in the per protocol (PP) analysis.

Prespecified subgroup analyses were performed for the primary endpoint, DoCE, with respect to diabetes, ST-segment elevation MI (STEMI), small vessels ( $\leq 2.75$  mm), multivessel treatment, long lesions ( $> 18$  mm), in-stent restenosis, bypass graft, left main treatment, bifurcation treatment, or overlapping stents.

The cumulative event rates were estimated using the Kaplan-Meier method and comparisons of outcomes were performed with the log-rank test. Hazard ratios were calculated using the Cox proportional hazards model. P values are for the superiority and a two-sided p-value  $< 0.05$  was considered statistically significant. Analyses were performed using SAS software, version 9.3 (SAS Institute Inc.) and R version 3.6.0 (R Foundation for Statistical Computing).


## Results

### STUDY POPULATION

The TALENT trial enrolled 1,435 patients with 2,076 lesions; 720 patients with 1,046 lesions were randomly assigned to Supraflex, and 715 patients with 1,030 lesions to XIENCE (Figure 1). Baseline clinical, angiographic, and procedural characteristics were comparable between the two groups, as previously reported<sup>15</sup>. Three-year follow-up data were available for 97.8% (704/720) of patients in the Supraflex group and for 98.9% (707/715) of patients in the XIENCE group (Figure 1).

### CLINICAL OUTCOMES AT 3 YEARS (ITT ANALYSIS)

At 3 years DoCE occurred in 57 patients (8.1%) in the Supraflex group, and in 66 patients (9.4%) in the XIENCE group (difference  $-1.3\%$  [95% CI:  $-4.3\%$  to  $1.6\%$ ];  $p=0.406$ ) (Table 1, Figure 2A). There were no significant between-group differences in rates of cardiac death, TV-MI, and CI-TLR (Table 1, Figure 2B-Figure 2D).



**Figure 1.** Study follow chart. EES: everolimus-eluting stent; SES: sirolimus-eluting stent.

There were also no significant differences in the groups between 1 and 3 years (Supplementary Figure 1). The percentages of patients with DAPT at 6 and 12 months were similar (Supplementary Table 2), and the rates of definite or probable stent thrombosis were low and comparable (Supraflex 1.1% vs XIENCE 1.4%, difference  $-0.4\%$  [95% CI:  $-1.5\%$  to  $0.7\%$ ];  $p=0.640$ ) (Table 1, Figure 2E). The rates of other clinical events are presented in Table 1. Non-TV revascularisation was significantly lower in the XIENCE group (5.7%), compared to the Supraflex group (8.6%) (difference  $2.9\%$  [95% CI:  $0.2\%$  to  $5.6\%$ ];  $p=0.035$ ), although these events were not associated with lesions treated with study stents.

### PER PROTOCOL (PP) ANALYSIS

In the PP analysis at 3 years DoCE occurred in 43 (6.6%) patients treated with Supraflex and 59 (8.7%) patients treated with XIENCE (difference  $-2.1\%$  [95% CI:  $-5.0\%$  to  $0.8\%$ ],  $p=0.165$ ) (Supplementary Table 3, Supplementary Figure 2A). The rates of cardiac death, TV-MI and CI-TLR were all numerically lower, but not statistically different with Supraflex compared with XIENCE. Notably the significantly lower rate of CI-TLR observed with Supraflex in the PP analysis at 1-year (1.2% vs 3.1%, difference  $-1.9\%$  [95% CI:  $-3.5\%$  to  $0.3\%$ ],  $p=0.021$ )<sup>6</sup> was no longer evident at 3 years (3.6% vs 5.1%, difference  $-1.5\%$ , [95% CI:  $-3.7$  to  $0.7$ ],  $p=0.192$ ) (Supplementary Table 3, Supplementary Figure 2B-Supplementary Figure 2D). There were no significant differences between stents in rates of non-TV revascularisation (Supraflex 7.8% vs XIENCE 5.8%, difference  $2.0\%$  [95% CI:  $-0.7\%$  to  $4.7\%$ ],  $p=0.143$ ).

### SUBGROUP ANALYSIS

The treatment effect in DoCE was no different across the pre-specified subgroup analyses for diabetes, STEMI, multivessel treatment, long lesions, in-stent restenosis, bypass graft, left main treatment, bifurcation treatment, or overlapping stents, although Supraflex resulted in better outcomes in patients without small vessels treated (Figure 3).

**Table 1. Clinical outcomes at 36 months after stent implantation.**

Clinical outcomes (ITT)	Supraflex SES (n=720)	XIENCE EES (n=715)	Difference (95% confidence interval)	p-value
DoCE	8.1 (57)	9.4 (66)	-1.3 (-4.3-1.6)	0.406
PoCE	18.0 (128)	16.5 (117)	1.5 (-2.5-5.4)	0.424
TVF	9.8 (69)	10.6 (75)	-0.9 (-4.0-2.3)	0.604
<b>Components of composite endpoints</b>				
Death	4.2 (30)	4.8 (34)	-0.6 (-2.7-1.6)	0.619
Cardiac death	1.8 (13)	2.1 (15)	-0.3 (-1.8-1.2)	0.707
MI	5.3 (37)	6.0 (42)	-0.7 (-3.1-1.7)	0.563
Q-wave	0.9 (6)	1.0 (7)	-0.1 (-1.2-0.9)	0.785
Non-Q-wave	4.6 (32)	5.3 (37)	-0.7 (-3.0-1.5)	0.536
TV-MI	3.3 (23)	4.6 (32)	-1.3 (-3.3-0.7)	0.219
Q-wave	0.6 (4)	0.9 (6)	-0.3 (-1.2-0.6)	0.529
Non-Q-wave	2.8 (20)	3.9 (27)	-1.0 (-2.9-0.9)	0.300
Non-TV-MI	2.0 (14)	1.6 (11)	0.4 (-1.0-1.8)	0.545
Q-wave	0.3 (2)	0.1 (1)	0.1 (-0.4-0.6)	0.563
Non-Q-wave	1.7 (12)	1.6 (11)	0.2 (-1.2-1.5)	0.833
All revascularisation	13.3 (93)	11.6 (81)	1.7 (-1.8-5.2)	0.325
TL revascularisation	6.3 (44)	6.3 (44)	-0.0 (-2.5-2.5)	0.993
Clinically indicated	5.0 (35)	5.9 (41)	-0.9 (-3.2-1.5)	0.483
Non-clinically indicated	1.6 (11)	1.4 (10)	0.1 (-1.1-1.4)	0.827
TV revascularisation	8.0 (56)	8.2 (57)	-0.2 (-3.0-2.7)	0.922
Clinically indicated	6.9 (48)	7.6 (53)	-0.7 (-3.4-2.0)	0.603
Non-clinically indicated	1.6 (11)	2.0 (14)	-0.4 (-1.8-1.0)	0.543
Non-TV revascularisation	8.6 (60)	5.7 (40)	2.9 (0.2-5.6)	0.035
<b>Stent thrombosis</b>				
Definite	1.0 (7)	1.3 (9)	-0.3 (-1.4-0.8)	0.620
Definite (very late, >360 days)	0.3 (2)	0.6 (4)	-0.3 (-1.0-0.4)	0.419
Definite or probable	1.1 (8)	1.4 (10)	-0.3 (-1.5-0.9)	0.640
Definite or probable (very late, >360 days)	0.3 (2)	0.6 (4)	-0.3 (-1.0-0.4)	0.419

Data are presented as percentages (numbers). DoCE: device-oriented composite endpoint; ITT: intention-to-treat; MI: myocardial infarction; PoCE: patient-oriented composite endpoint; TL: target lesion; TV: target-vessel; TVF: target vessel failure

## META-ANALYSIS

Including the TALENT trial, there were 11 randomised trials (15,370 patients) with at least 3-year results comparing outcomes between ultrathin strut DES with thicker strut DES (Table 2, Supplementary Table 4, Supplementary Figure 3). Overall, ultrathin strut DES resulted in a 11% reduction in DoCE compared to thicker strut DES (RR 0.89, 95% CI: 0.79-1.01;  $p=0.068$ ), although the effect was not statistically significant (Figure 4). Ultrathin strut DES and thicker strut DES had similar risks for definite or probable stent thrombosis and mortality (Figure 4). Moderate heterogeneity was observed for DoCE and death, thus the L'Abbé plots are presented in Supplementary Figure 4. The funnel plots and risk of bias are shown in Supplementary Figure 5 and Supplementary Table 4.


In patients with diabetes or small vessel treated, there were no statistically significant differences in DoCE between ultrathin strut DES and the thicker strut DES (Supplementary Figure 6).

## Discussion


At 3-year follow-up of the randomised all-comers TALENT trial, there were no significant differences in rates of DoCE, its individual components, or stent thrombosis between patients assigned to the Supraflex or XIENCE groups (Central illustration, panel A).

### IMPACT OF THE SUPRAFLEX STENT ON REPEAT REVASCULARISATION

At 1-year follow-up in the PP analysis, the Supraflex stent resulted in a significantly lower rate of CI-TLR, compared to XIENCE. At 3-year follow-up, whilst the rate of CI-TLR was still numerically lower with Supraflex, the difference was no longer statistically significant (5.0% vs 5.9%;  $p=0.483$  [ITT analysis]; 3.6% vs 5.1%;  $p=0.192$  [PP analysis]). Longer follow-up and/or a larger sample size are certainly needed to fully examine how this early difference could be more durable.



**Figure 2.** Kaplan-Meier estimates for the device-oriented composite endpoint (DoCE) and its components at 3 years (intention-to-treat [ITT] basis). A) DoCE, B) cardiac death, C) target vessel myocardial infarction (TV-MI), D) clinically indicated target lesion revascularisation (CI-TLR), and E) definite or probable stent thrombosis. HR: hazard ratio.



**Figure 3.** Subgroup analysis for DoCE (ITT basis). STEMI: ST-elevation myocardial infarction

### IMPACT OF ULTRATHIN STRUT POLYMERS

A meta-analysis of 10 randomised trials including 11,658 patients by Bangalore et al demonstrated that at 1-year ultrathin strut DES (Orsiro, MiStent, and BioMime) resulted in a 16% RR reduction in





DoCE (RR 0.84, 95% CI: 0.72-0.99), compared to second-generation DES with thicker struts (XIENCE, Resolute, and Nobori)<sup>16</sup>. Recently, another meta-analysis at a mean follow-up of 2.5 years demonstrated that ultrathin strut DES reduced the risk of DoCE (RR

**Table 2.** Clinical randomised trials for a meta-analysis.


Study	Publication	Follow-up	Comparisons	Population	Number of patients	DoCE	Cardiac death	TV-MI	CI-TLR	Definite or probable stent thrombosis
BIOSCIENCE <sup>18</sup>	2018	5 years	Orsiro vs XIENCE	All-comers	1,063 vs 1,056	20.2% vs 18.8%	8.6% vs 7.5%	6.3% vs 7.1%	10.8% vs 10.0%	6.3% vs 7.7%
BIOFLOW II <sup>19</sup>	2018	5 years	Orsiro vs XIENCE	All-comers	298 vs 154	10.4% vs 12.7%	1.7% vs 2.8%	3.4% vs 3.3%	6.3% vs 6.7%	0.0% vs 0.7%
BIOFLOW IV	2019	4 years	Orsiro vs XIENCE	All-comers	385 vs 190	NA	NA	NA	NA	0.8% vs 0.0%
BIOFLOW V <sup>20</sup>	2020	3 years	Orsiro vs XIENCE	Non-all-comers	884 vs 450	8.2% vs 13.6%	1.1% vs 1.2%	5.0% vs 9.2%	3.2% vs 6.7%	0.5% vs 1.5%
BIO-RESORT <sup>21</sup>	2019	3 years	Orsiro vs Resolute Integrity	All-comers	1,169 vs 1,173	6.7% vs 8.3%	2.1% vs 2.3%	3.0% vs 3.5%	2.9% vs 3.8%	1.1% vs 0.9%
PRISON-IV <sup>22</sup>	2019	3 years	Orsiro vs XIENCE	Chronic total occlusion	165 vs 165	NA	1.2% vs 1.8%	NA	NA	NA
ORIENT <sup>23</sup>	2020	3 years	Orsiro vs Resolute Integrity	All-comers	250 vs 122	4.7% vs 7.8%	0.8% vs 2.6%	NA	3.8% vs 5.2%	0.0% vs 1.6%
SORT OUT VII <sup>24</sup>	2020	3 years	Orsiro vs Nobori	All-comers	1,261 vs 1,264	9.0% vs 9.1%*	3.0% vs 2.6%	3.1% vs 2.9%*	5.2% vs 5.9%	1.5% vs 2.1%
BIONYX <sup>25</sup>	2021	3 years	Orsiro vs Resolute Onyx	All-comers	1,245 vs 1,243	7.5% vs 7.2%	1.9% vs 1.1%	3.1% vs 3.2%	4.6% vs 4.7%	1.2% vs 0.6%
DESSOLVE III <sup>26</sup>	2020	3 years	MiStent vs XIENCE	All-comers	703 vs 695	10.5% vs 11.5%*	3.9% vs 3.8%	3.2% vs 2.5%*	5.2% vs 6.5%	1.2% vs 1.5%
TALENT	2021	3 years	Supraflex vs XIENCE	All-comers	720 vs 715	8.1% vs 9.4%	1.8% vs 2.1%	3.3% vs 4.6%	5.0% vs 5.9%	1.1% vs 1.4%

\*In the SORT OUT VII and DESSOLVE III trials, MI not clearly attributable to a non-target vessel was used, instead of TV-MI. CI-TLR: clinical indicated target lesion revascularisation



**A DoCE****B Cardiac death****C TV-MI****D CI-TLR**


**Figure 4.** Long-term outcomes of ultrathin strut DES vs thicker strut DES. A) DoCE, B) cardiac death, C) TV-MI, D) CI-TLR, E) definite or probable stent thrombosis, and F) death. In the BIOFLOW V trial, DoCE was defined as cardiovascular death, TV-MI, or ischaemia-driven TLR. In the SORT OUT VII and DESSOLVE III trials, MI not clearly attributable to a non-target vessel was used, instead of TV-MI. CI: confidence interval; CI-TLR: clinically indicated target lesion revascularisation; DoCE: device-oriented composite endpoint; TV-MI: target-vessel myocardial infarction



**Figure 4. (cont'd)** Long-term outcomes of ultrathin strut DES vs thicker strut DES. A) DoCE, B) cardiac death, C) TV-MI, D) CI-TLR, E) definite or probable stent thrombosis, and F) death. In the BIOFLOW V trial, DoCE was defined as cardiovascular death, TV-MI, or ischaemia-driven TLR. In the SORT OUT VII and DESSOLVE III trials, MI not clearly attributable to a non-target vessel was used, instead of TV-MI. CI: confidence interval; CI-TLR: clinically indicated target lesion revascularisation; DoCE: device-oriented composite endpoint; TV-MI: target-vessel myocardial infarction

0.85, 95% CI: 0.76-0.96), driven by less CI-TLR (RR 0.75, 95% CI: 0.62-0.92) compared with second-generation DES with thicker struts, with similar risks of cardiac death, and all-cause death<sup>17</sup>.

In the TALENT trial, the ultrathin strut Supraflex stent reduced DoCE at 1 year by 6%, compared to the thin strut XIENCE stent in the ITT analysis<sup>6</sup>. The effect of the ultrathin strut Supraflex



**Central illustration.** Results of the TALENT trial and a long-term meta-analysis. A) Three-year results of the TALENT trial. B) Long-term (3-5 years) results of a meta-analysis. CI: confidence interval; CI-TLR: clinically indicated target lesion revascularisation; EES: everolimus-eluting stent; DoCE: device-oriented composite endpoint; HR: hazard ratio; RR: relative risk; SES: sirolimus-eluting stent; TV-MI: target vessel myocardial infarction



stent was retained at 3 years with 14% risk reductions in DoCE, although the effect was not statistically significant.

To date, long-term follow-up data with at least 3-year results of ultrathin strut stents (strut thickness  $<70\ \mu\text{m}$ ) versus thicker strut stents (strut thickness  $\geq 81\ \mu\text{m}$ ) are available in the BIOSCIENCE<sup>18</sup>, BIOFLOW II<sup>19</sup>, BIOFLOW V<sup>20</sup>, BIO-RESORT<sup>21</sup>, PRISON-IV<sup>22</sup>, ORIENT<sup>23</sup>, SORT OUT VII<sup>24</sup>, BIONYX<sup>25</sup> (Orsiro), DESOLVE III<sup>26</sup> (MiStent), and TALENT (Supraflex) randomised trials. The 4-year results of BIOFLOW-IV have not been published, but have been presented in Slagboom et al. TCT-43 A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-Eluting Stent in the Treatment of Subjects With Up to 2 *De Novo* Coronary Artery Lesions—BIOFLOW IV: 4-Year Clinical Results. *J Am Coll Cardiol.* 2019;74:B43. The characteristics of these ultrathin strut stents are shown in **Table 3**<sup>16,27,28</sup>.

Our updated meta-analysis of these trials, including results from the current study, demonstrate the safety of ultrathin strut DES compared to thicker strut DES at a minimum of 3 years follow-up (**Central illustration**, panel B). Although moderate heterogeneity was observed between studies and the difference was not statistically significant, ultrathin strut DES reduced DocE by 11%, compared to thicker strut DES (RR 0.89, 95% CI: 0.79-1.01;  $p=0.068$ ). The risks for cardiac death and definite or probable stent thrombosis were similar between ultrathin strut DES and thicker strut DES. Theoretically, thinner struts could have some advantages: such as less stent-induced vessel injury and subsequent inflammation; faster re-endothelialisation; and less flow disturbance and fewer areas of low shear stress behind struts, resulting in reduced thrombogenicity<sup>1-4,29</sup>. The stent strut thickness of Orsiro is  $80\ \mu\text{m}$  for stent diameters  $\geq 3.5\ \text{mm}$ , which was similar to the stent strut thickness of XIENCE stent ( $81\ \mu\text{m}$  for all sizes) and Resolute Onyx stent ( $81\ \mu\text{m}$  for stent diameters  $\leq 4.0\ \text{mm}$ ). The patients treated with Orsiro with a stent diameter  $\geq 3.5\ \text{mm}$  may dilute the impact of stent strut thickness. At least, in the BIOSCIENCE trial, 244 patients (23.0%) were treated with stents  $\geq 3.5\ \text{mm}$  in the Orsiro group. Thus, the

meta-analysis may underestimate the impact of stent strut thickness, and the analysis using individual patient data is mandatory to investigate the impact of ultrathin strut DES precisely.

### COMPARISON BETWEEN NEWER-GENERATION ULTRATHIN STRUT DES

There are notable differences in stent profiles amongst the ultrathin strut Orsiro, MiStent, and Supraflex DES. The Supraflex and MiStent DES have a fixed strut thickness of 60 and  $64\ \mu\text{m}$ , respectively, irrespective of the stent diameter, which is at variance with the Orsiro stent, which has a strut thickness of  $60\ \mu\text{m}$  for stents 2.25 to 3.0 mm in diameter and  $80\ \mu\text{m}$  for stents with a diameter of 3.5 to 4.0 mm. Moreover, whilst these ultrathin strut stents all have biodegradable polymers and elute sirolimus, there are fundamental differences in their drug release kinetics.

In the Supraflex stent, 70% of the sirolimus is eluted in the first 7 days during an initial burst, followed by sustained release which is completed by day 48; the polymer gradually degrades over 9-12 months. In the MiStent, no drug release occurs in the first 3 days, and whilst the polymer is fully biodegraded and resorbed within 3 months of implantation, microcrystalline sirolimus is impacted and embedded in the vessel wall, acting as a tissue reservoir for 270 days, such that arterial concentrations of sirolimus still reach more than 2 ng/ml at day 270. In the Orsiro stent, sirolimus is slowly released over 12-14 weeks, whilst its polymer completely degrades within 12-24 months. Although the rate of DoCE at 3 years with the MiStent in the all-comers DESOLVE III trial was 10.2% (72 patients out of 703 patients, Kaplan-Meier estimated rate 10.5%), the rate of DoCE at 3 years were lower in all-comers population treated with the Supraflex stents (57 patients [7.9%; Kaplan-Meier estimated rate 8.1%] out of 720 patients in the TALENT trial) (**Table 2**). The rate of DoCE at 3 years in all-comers population treated with the Orsiro was available in the BIO-RESORT, ORIENT, SORT OUT VII, and BIONYX trials, and was 7.5% (293 patients out of 3,925 patients).

**Table 3. Characteristics of stents.**

	Orsiro	MiStent	Supraflex	XIENCE	Resolute Integrity	Resolute Onyx	Nobori
Platform material	Cobalt chromium	Cobalt chromium	Cobalt chromium	Cobalt chromium	Cobalt chromium	Cobalt chromium, platinum-iridium core wire	Stainless steel
Strut thickness	60/80 $\mu\text{m}^*$	64 $\mu\text{m}$	60 $\mu\text{m}$	81 $\mu\text{m}$	91 $\mu\text{m}$	81/91 $\mu\text{m}^{**}$	120 $\mu\text{m}$
Polymer thickness	7.4 $\mu\text{m}$ abluminal 3.5 $\mu\text{m}$ luminal	15 $\mu\text{m}$ abluminal 5 $\mu\text{m}$ luminal	4-5 $\mu\text{m}$ abluminal 4-5 $\mu\text{m}$ luminal	7.6 $\mu\text{m}$ for both sides	5.3 $\mu\text{m}$ for both sides	5.6 $\mu\text{m}$ for both sides	10 $\mu\text{m}$ abluminal
Polymer coating	Biodegradable	Biodegradable	Biodegradable	Durable	Durable	Durable	Biodegradable
Biodegradation of polymer	12-24 months	3 months	9-12 months	NA	NA	NA	6-9 months
Drug eluted	Sirolimus	Sirolimus	Sirolimus	Everolimus	Zotarolimus	Zotarolimus	Biolimus A9
Drug dose	1.4 $\mu\text{g}/\text{mm}^2$	2.4 $\mu\text{g}/\text{mm}^2$	1.4 $\mu\text{g}/\text{mm}^2$	100 $\mu\text{g}/\text{cm}^2$	1.6 $\mu\text{g}/\text{mm}^2$	1.6 $\mu\text{g}/\text{mm}^2$	15.6 $\mu\text{g}/\text{mm}^2$
Drug release	3 months	9 months	48 days	4 months	6 months	6 months	30 days

\*60  $\mu\text{m}$  for stents  $\leq 3.0\ \text{mm}$  and 80  $\mu\text{m}$  for stents  $\geq 3.5\ \text{mm}$ ; \*\*81  $\mu\text{m}$  for stents  $\leq 4.0\ \text{mm}$  and 91  $\mu\text{m}$  for stents  $\geq 4.5\ \text{mm}$

## Limitations

The TALENT trial was single-blinded, although the effect of this approach on event reporting is minimal because of the adjudication by an independent blinded clinical event committee. The study did not have adequate statistical power for any individual endpoints due to its relatively small sample size.

In terms of meta-analysis, the definitions of DoCE were not the same in each trial (e.g., TV-MI or MI not clearly attributable to a non-target vessel, etc). The definition of MI was not consistent across trials (e.g., SCAI definition, universal definition of myocardial infarction, WHO's extended definition, criteria of cardiac biomarkers, etc). Furthermore, long-term results of DoCE were not available for the BIOFLOW-IV and PRISON IV trials. Longer-term follow-up and large-scale individual data are necessary to investigate long-term benefits of ultrathin strut DES.

## Conclusions

In the present final report of the TALENT trial, the use of the Supraflex ultrathin strut stent was at least as safe and efficacious as the XIENCE stent at 3 years in an all-comers population.

### Impact on daily practice

Supraflex ultrathin strut stent was at least as safe and efficacious as the XIENCE stent at 3 years in an all-comers population. In a meta-analysis of long-term follow-up (3-5 years), ultrathin strut DES was also as safe and efficacious as thicker strut DES. Ultrathin strut DES can be considered for PCI.

## Funding

This study was sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, the Netherlands), and supported with an unrestricted grant from Sahajanand Medical Technologies (Surat, India). ECRI funded the independent clinical research organisation Cardialysis for site management, safety reporting, data management, endpoint adjudication, database management, and statistical analyses.

## Role of the Funder/Sponsor

The study funders had no role in trial design, data collection, analysis, interpretation of the data, preparation, approval, or making a decision to submit the manuscript or publication.

## Acknowledgements

The authors would like to thank Anita van der Wal and Maurice Vorage as representatives of the study team at Cardialysis, Rotterdam for their operational contribution.

## Conflict of interest statement

H. Hara reports a grant for studying overseas from Japanese Circulation Society, a grant-in-Aid for JSPS Fellows, a grant-in-aid from the Japan Foundation for Applied Enzymology and a grant from the Fukuda Foundation for Medical Technology. P. Smits

reports grants and personal fees from Abbott Vascular, St. Jude Medical, and Terumo, outside the submitted work. S. Hofma reports unrestricted research grants from Abbott Vascular to The Research Department of the Division of Cardiology of the Medical Center Leeuwarden. R. Moreno reports lecture and consultant fees from Abbott Vascular, Boston Scientific, Biosensors, Biotronik, Daiichi-Sankyo, Ferrer, Philips, and Edwards; and research grants from Abbott Vascular, Boston Scientific, Biosensors, Daiichi-Sankyo, all outside of the submitted work. A. Zaman reports lecture fees from SMT and lecture/consulting fees from Abbott. I. Petrov reports lecture fees and proctor honoraria from Medtronic, Contego, Edwards, Amgen, Cardiatis, Abbott Vascular and Novartis, outside the submitted work. P.W. Serruys reports institutional grants from Philips/Volcano, Xeltis, Meril Life, Novartis and SMT, outside the submitted work. The other authors have no conflicts of interest to declare.

## References

- Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. *Circulation*. 2011;123:1400-9.
- Koppara T, Cheng Q, Yahagi K, Mori H, Sanchez OD, Feygin J, Wittchow E, Kolodgie FD, Virmani R, Joner M. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. *Circ Cardiovasc Interv*. 2015;8:e002427.
- Thondapu V, Tenekecioglu E, Poon EKW, Collet C, Torii R, Bourantas CV, Chin C, Sotomi Y, Jonker H, Dijkstra J, Revalor E, Gijzen F, Onuma Y, Ooi A, Barlis P, Serruys PW. Endothelial shear stress 5 years after implantation of a coronary biore-sorbable scaffold. *Eur Heart J*. 2018;39:1602-9.
- Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. *J Am Coll Cardiol*. 2012;59:1337-49.
- Modolo R, Chichareon P, Kogame N, Asano T, Chang CC, de Winter RJ, Kaul U, Zaman A, Spitzer E, Takahashi K, Katagiri Y, Soliman OII, van Es GA, Morel MA, Onuma Y, Serruys PW. A prospective multicentre randomised all-comers trial to assess the safety and effectiveness of the thin-strut sirolimus-eluting coronary stent SUPRAFLEX: rationale and design of the Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) trial. *EuroIntervention*. 2019;15:e362-9.
- Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopcuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoyer A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Jusselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW. TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. *Lancet*. 2019;393:987-97.
- Gao C, Kogame N, Sharif F, Smits PC, Tonino P, Hofma S, Moreno R, Choudhury A, Petrov I, Cequier A, Colombo A, Kaul U, Zaman A, de Winter RJ, Onuma Y, Serruys PW. Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex: Two-Year Outcomes of the TALENT Trial. *Circ Cardiovasc Interv*. 2021;14:e010312.
- Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation*. 2007;115:2344-51.
- Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). *J Am Coll Cardiol*. 2013;62:1563-70.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK,

- Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiadu M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ and Mendis S. Third universal definition of myocardial infarction. *Circulation*. 2012;126:2020-35.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-88.
12. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21:1539-58.
13. Borenstein M, Higgins JP, Hedges LV, Rothstein HR. Basics of meta-analysis:  $I^2$  is not an absolute measure of heterogeneity. *Res Synth Methods*. 2017;8:5-18.
14. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
15. de Winter RJ, Katagiri Y, Asano T, Milewski KP, Lurz P, Buszman P, Jessurun GAJ, Koch KT, Troquay RPT, Hamer BJB, Ophuis TO, Wöhrle J, Wyderka R, Cayla G, Hofma SH, Levesque S, Zurakowski A, Fischer D, Kośmider M, Goube P, Arkenbout EK, Noutsias M, Ferrari MW, Onuma Y, Wijns W, Serruys PW. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. *Lancet*. 2018;391:431-40.
16. Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. *Circulation*. 2018;138:2216-26.
17. Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M, Shahim B, Leon MB, Bangalore S, Stone GW, Ahmad Y. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. *Eur Heart J*. 2021;42:2643-54.
18. Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Muller O, Moarof I, Siontis GCM, Cook S, Weilenmann D, Kaiser C, Cuculi F, Hunziker L, Eberli FR, Juni P, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet*. 2018;392:737-46.
19. Lefèvre T, Haude M, Neumann FJ, Stangl K, Skurk C, Slagboom T, Sabaté M, Goicolea J, Barragan P, Cook S, Macia JC, Windecker S. Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial. *JACC Cardiovasc Interv*. 2018;11:995-1002.
20. Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial. *JACC Cardiovasc Interv*. 2020;13:1343-53.
21. Buiten RA, Ploumen EH, Zocca P, Doggen CJM, Danse PW, Schotborgh CE, Scholte M, van Houwelingen KG, Stoel MG, Hartmann M, Tjon Joe Gin RM, Smit S, Linssen GCM, Kok MM, von Birgelen C. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT. *JACC Cardiovasc Interv*. 2019;12:1650-60.
22. Zivelonghi C, Agostoni P, Teeuwen K, van der Schaaf RJ, Henriques JPS, Vermeersch PHMJ, Bosschaert MAR, Kelder JC, Tijssen JGP, Suttrop MJ. 3-Year Clinical Outcomes of the PRISON-IV Trial: Ultrathin Struts Versus Conventional Drug-Eluting Stents in Total Coronary Occlusions. *JACC Cardiovasc Interv*. 2019;12:1747-9.
23. Kim SH, Kang SH, Lee JM, Chung WY, Park JJ, Yoon CH, Suh JW, Cho YS, Doh JH, Cho JM, Bae JW, Yoon TJ, Chae IH. Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial. *Catheter Cardiovasc Interv*. 2020;96:1399-406.
24. Ellert J, Maeng M, Raugaard B, Hansen KN, Kahlert J, Jensen SE, Bøtker HE, Hansen HS, Lassen JF, Christiansen EH, Jensen LO. Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial. *Coron Artery Dis*. 2020;31:485-92.
25. Ploumen EH, Buiten RA, Zocca P, Doggen CJ, Aminian A, Schotborgh CE, Jessurun GA, Roguin A, Danse PW, Benit E, von Birgelen C. First Report of 3-Year Clinical Outcome After Treatment With Novel Resolute Onyx Stents in the Randomized BIONYX Trial. *Circ J*. 2021;85:1983-90.
26. Takahashi K, Serruys PW, Kogame N, Buszman P, Lurz P, Jessurun GAJ, Koch KT, Troquay RPT, Hamer BJB, Oude Ophuis T, Milewski KP, Hofma SH, Wykrzykowska JJ, Onuma Y, de Winter RJ, Wijns W. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial. *Circ Cardiovasc Interv*. 2020;13:e008737.
27. Ono M, Takahashi K, Gao C, Kawashima H, Wu X, Hara H, Wang R, Wykrzykowska JJ, Piek JJ, Sharif F, Serruys PW, Wijns W, Onuma Y. The state-of-the-art coronary stent with crystallized sirolimus: the MiStent technology and its clinical program. *Future Cardiol*. 2021;17:593-607.
28. Gao C, Kogame N, Modolo R, Takahashi K, Wang R, Kawashima H, Ono M, Hara H, Tomaniak M, Zaman A, de Winter RJ, van Geuns RJ, Kaul U, Serruys PW, Onuma Y. The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX. *Future Cardiol*. 2021;17:227-37.
29. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schühlen H, Neumann FJ, Fleckenstein M, Pfaffert C, Seyfarth M, Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STREO) trial. *Circulation*. 2001;103:2816-21.

## Supplementary data

**Supplementary Table 1.** Search syntax.

**Supplementary Table 2.** Patients with DAPT.

**Supplementary Table 3.** Clinical outcomes at 36 months after stent implantation (per protocol [PP] basis).

**Supplementary Table 4.** Risk of bias.

**Supplementary Figure 1.** Kaplan-Meier estimates for the device-oriented composite endpoint (DoCE) and its components between 1 and 3 years (intention-to-treat [ITT] basis).

**Supplementary Figure 2.** Kaplan-Meier estimates for the DOCE and its components at 3 years (per protocol [PP] basis).

**Supplementary Figure 3.** Flow chart for randomised control trials included in the meta-analysis.

**Supplementary Figure 4.** L'Abbé plots for the meta-analysis comparing ultrathin strut DES and thicker strut DES.

**Supplementary Figure 5.** Funnel plots for long-term meta-analysis.

**Supplementary Figure 6.** Long-term outcomes of ultrathin strut DES vs thicker strut DES in patients with diabetes and small vessel treated.

The supplementary data are published online at:

<https://eurointervention.pcronline.com/>

doi/10.4244/EIJ-D-21-00766



## Supplementary data

**Supplementary Table 1. Search syntax.**

Database	Search term
PubMed	Filter: 2010-2021 ("ultra-thin"[Title/Abstract] OR "ultrathin"[Title/Abstract] OR "very thin"[Title/Abstract] OR "Orsiro"[Title/Abstract] OR "Mistent"[Title/Abstract] OR "Supraflex"[Title/Abstract] OR "Supralimus"[Title/Abstract] OR "BioMime"[Title/Abstract]) AND ("DES"[Title/Abstract] OR "stents"[Title/Abstract] OR "stent"[Title/Abstract])
EMBASE	ultra thin':ab,ti OR ultrathin:ab,ti OR 'very thin':ab,ti OR orsiro:ab,ti OR mistent:ab,ti OR supraflex:ab,ti OR supralimus:ab,ti OR biomime:ab,ti) AND ('des':ab,ti OR 'stent':ab,ti OR 'stents':ab,ti) AND [randomized controlled trial]/lim AND [2010-2021]/py

**Supplementary Table 2. Patients with DAPT.**

		<b>Supraflex SES (n=720)</b>	<b>XIENCE EES (n=715)</b>	<b>Difference (95% confidence interval)</b>	<b>p- value</b>
6 months	Patients with stable CAD	85.8% (242/282)	86.5% (262/303)	-0.7% (-6.3%, 5.0%)	0.905
	Patients with ACS	90.1% (372/413)	92.2% (367/398)	-2.1% (-6.0%, 1.8%)	0.324
12 months	Patients with stable CAD	83.7% (231/276)	85.1% (257/302)	-1.4% (-7.3%, 4.5%)	0.648
	Patients with ACS	79.7% (325/408)	81.2% (320/394)	-1.6% (-7.1%, 3.9%)	0.594

ACS: acute coronary syndrome; CAD: coronary artery disease; DAPT: dual antiplatelet therapy

**Supplementary Table 3. Clinical outcomes at 36 months after stent implantation (per protocol [PP] basis).**

<b>Clinical outcomes (PP)</b>	<b>Supraflex SES (n=660)</b>	<b>XIENCE EES (n=685)</b>	<b>Difference (95% confidence interval)</b>	<b>p-value</b>
DoCE	6.6% (43)	8.7% (59)	-2.1% (-5.0%,0.8%)	0.165
PoCE	16.5% (107)	15.5% (105)	1.0% (-3.0%,4.9%)	0.588
TVF	8.4% (54)	9.9% (67)	-1.6% (-4.7%,1.5%)	0.336
Components of composite endpoints				
Death	4.2% (27)	4.6% (31)	-0.4% (-2.6%,1.8%)	0.728
Cardiac death	1.9% (12)	2.2% (15)	-0.4% (-1.9%,1.1%)	0.649
MI	5.1% (33)	5.8% (39)	-0.7% (-3.1%,1.8%)	0.596
Q-wave	0.8% (5)	0.9% (6)	-0.1% (-1.1%,0.9%)	0.825
Non-Q-wave	4.5% (29)	5.1% (34)	-0.5% (-2.9%,1.8%)	0.644
TV-MI	2.9% (19)	4.6% (31)	-1.7% (-3.7%,0.4%)	0.119
Q-wave	0.5% (3)	0.9% (6)	-0.4% (-1.3%,0.5%)	0.353
Non-Q-wave	2.6% (17)	3.9% (26)	-1.2% (-3.1%,0.7%)	0.214
Non-TV-MI	2.2% (14)	1.4% (9)	0.9% (-0.6%,2.3%)	0.243
Q-wave	0.3% (2)	0.0% (0)	0.3% (-0.1%,0.8%)	0.147
Non-Q-wave	1.9% (12)	1.4% (9)	0.5% (-0.8%,1.9%)	0.441
All revascularisation	11.9% (76)	10.7% (72)	1.1% (-2.3%,4.6%)	0.502
TL revascularisation	4.8% (31)	5.4% (36)	-0.5% (-2.9%,1.9%)	0.677
clinically indicated	3.6% (23)	5.1% (34)	-1.5% (-3.7%,0.7%)	0.192
non-clinically indicated	1.6% (10)	1.0% (7)	0.5% (-0.7%,1.7%)	0.407
TV revascularisation	6.6% (42)	7.2% (48)	-0.6% (-3.3%,2.1%)	0.675
clinically indicated	5.5% (35)	6.7% (45)	-1.2% (-3.8%,1.3%)	0.346




non-clinically indicated	1.6% (10)	1.5% (10)	0.1% (-1.3%,1.4%)	0.915
Non-TV revascularisation	7.8% (50)	5.8% (39)	2.0% (-0.7%,4.7%)	0.143
Stent thrombosis				
Definite	0.8% (5)	1.2% (8)	-0.4% (-1.5%,0.7%)	0.455
Definite (very late, >360 days)	0.3% (2)	0.5% (3)	-0.1% (-0.8%,0.5%)	0.699
Definite or probable	0.9% (6)	1.3% (9)	-0.4% (-1.5%,0.7%)	0.495
Definite or probable (very late, >360 days)	0.3% (2)	0.5% (3)	-0.1% (-0.8%,0.5%)	0.699

Data are presented as percentage (number).


DoCE: device-oriented composite endpoint; MI: myocardial infarction; PoCE: patient-oriented composite endpoint; TL: target lesion; TV: target-vessel; TVF: target vessel failure

**Supplementary Table 4. Risk of bias.**

	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
BIOSCIENCE	Low	Low	High	Low	Low	Low
BIOFLOW II	Low	Low	High	Low	Low	Low
BIOFLOW IV	Low	Low	High	High	Low	High
BIOFLOW V	Low	Low	High	Low	Low	Low
BIO-RESORT	Low	Low	Low	Low	Low	Low
PRISON-IV	Low	Low	Low	Low	Low	High
ORIENT	Low	Low	High	Low	Low	Low
SORT OUT VII	Low	Low	High	Low	Low	Low
BIONYX	Low	Low	Low	Low	Low	Low
DESSOLVE III	Low	Low	Low	Low	Low	Low
TALENT	Low	Low	Low	Low	Low	Low




**Supplementary Figure 1.** Kaplan-Meier estimates for the device-oriented composite endpoint (DoCE) and its components between 1 and 3 years (intention-to-treat [ITT] basis). (A) DoCE, (B) cardiac death, (C) target vessel myocardial infarction (TV-MI), (D) clinical indicated target lesion revascularisation (CI-TLR), and (E) definite or probable stent thrombosis.




**Supplementary Figure 2.** Kaplan-Meier estimates for the DOCE and its components at 3 years (per protocol [PP] basis).

(A) DoCE, (B) cardiac death, (C) TV-MI, (D) CI-TLR, and (E) definite or probable stent thrombosis. HR: hazard ratio




**Supplementary Figure 3.** Flow chart for randomised control trials included in the meta-analysis.

**A DoCE**



**B Death**




**Supplementary Figure 4.** L'Abbé plots for the meta-analysis comparing ultrathin strut DES and thicker strut DES.


(A) DoCE, and (B) death. DES: drug-eluting stent




**A DoCE**




**B Cardiac death**




**C TV-MI**




**D CI-TLR**



**E Definite or probable stent thrombosis**




**F Death**




**Supplementary Figure 5.** Funnel plots for long-term meta-analysis.

(A) DoCE, (B) cardiac death, (C) TV-MI, (D) CI-TLR, (E) definite or probable stent thrombosis, and (F) death.

### A Any diabetes



### B Any small vessel treated



**Supplementary Figure 6.** Long-term outcomes of ultrathin strut DES vs thicker strut DES in patients with diabetes and small vessel treated.

Long-term meta-analysis in patients with (A) diabetes, and (B) small vessel treated.